Kura Oncology Inc reports results for the quarter ended September 30 - Earnings Summary

Kura Oncology

08/11/2024 21:03

* Kura Oncology Inc  KURA.OQ  reported a quarterly adjusted
loss
of 63 cents​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -50 cents.  The mean expectation of fifteen analysts for
the quarter was for a loss of 63 cents per share. Wall Street
expected results to range from -67 cents to -57 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kura Oncology Inc's reported EPS for the quarter was a
loss
of 63 cents​.
    * The company reported a quarterly loss of $54.4 million.
    * Kura Oncology Inc shares had fallen by 9.1% this
quarter and
gained 23.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.6%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Kura Oncology Inc
is $32.00 
This summary was machine generated from LSEG data November 8 at
09:03 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.63          -0.63          Met
 Jun. 30 2024      -0.63          -0.59          Beat
 Mar. 31 2024      -0.55          -0.59          Missed
 Dec. 31 2023      -0.55          -0.55          Met